Associated Genetic Biomarkers
Associated Diseases
Associated Pathways

Overview

Location [1]
13q12.2
Pathway
Receptor tyrosine kinase/growth factor signaling
Protein [2]
Receptor-type tyrosine-protein kinase FLT3
Synonyms [1]
STK1, CD135, FLK2, FLK-2

FLT3 (fms-related tyrosine kinase 3) encodes for the receptor-type tyrosine-protein kinase FLT3. FLT3 activates pathways in hematopoietic cells (Gene 2013). FLT3 is frequently mutated in acute myeloid leukemia, other hematologic malignancies, and colorectal cancer (COSMIC).

FLT3 is altered in 2.79% of all cancers with acute myeloid leukemia, colon adenocarcinoma, lung adenocarcinoma, cutaneous melanoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].

FLT3 GENIE Cases - Top Diseases

The most common alterations in FLT3 are FLT3 Mutation (2.20%), FLT3 Exon 14 Mutation (0.47%), FLT3 Amplification (0.49%), FLT3 D7G (14.38%), and FLT3 Exon 20 Mutation (0.23%) [3].

FLT3 GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of FLT3 in Diseases

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Acute Lymphoblastic Leukemia +

Chronic Myeloid Leukemia +

Chronic Myelomonocytic Leukemia +

Hodgkin Lymphoma +

Multiple Myeloma +

Non-Hodgkin Lymphoma +

Acute Biphenotypic Leukemia +

Chronic Lymphocytic Leukemia +

Mantle Cell Lymphoma +

Acute Leukemia +

Burkitt Lymphoma +

Secondary Acute Myeloid Leukemia +

Myeloproliferative Neoplasm +

Anaplastic Large Cell Lymphoma +

Follicular Lymphoma +

Marginal Zone Lymphoma +

B-Cell Acute Lymphoblastic Leukemia +

Juvenile Myelomonocytic Leukemia +

Myelodysplastic/Myeloproliferative Neoplasm +

Lymphoma +

Myelofibrosis +

Prolymphocytic Leukemia +

Therapy-Related Acute Myeloid Leukemia +

Malignant Solid Tumor +

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +

Refractory Anemia With Excess Blasts +

Small Lymphocytic Lymphoma +

Mixed Phenotype Acute Leukemia +

Lymphoplasmacytic Lymphoma +

Diffuse Large B-Cell Lymphoma +

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome +

Lymphoblastic Lymphoma +

T-Cell Acute Lymphoblastic Leukemia +

Acute Promyelocytic Leukemia +

B-Cell Non-Hodgkin Lymphoma +

Acute Undifferentiated Leukemia +

Adult T-Cell Leukemia/Lymphoma +

Double-Hit Lymphoma +

Mature T-Cell And NK-Cell Lymphoma/Leukemia +

Myelodysplastic Syndrome With Excess Blasts-2 +

Therapy-Related Myelodysplastic Syndrome +

T-Cell Lymphoblastic Leukemia/Lymphoma +

Plasma Cell Leukemia +

T-Cell Prolymphocytic Leukemia +

Myeloid Sarcoma +

Melanoma +

Waldenstrom Macroglobulinemia +

Colorectal Carcinoma +

Non-Small Cell Lung Carcinoma +

Bladder Carcinoma +

Mature T-Cell And NK-Cell Neoplasm +

Ovarian Carcinoma +

Head And Neck Carcinoma +

Breast Carcinoma +

Pancreatic Carcinoma +

Acute Erythroid Leukemia +

Acute Megakaryoblastic Leukemia +

B-Cell Prolymphocytic Leukemia +

Burkitt Leukemia +

Natural Killer Cell Lymphoblastic Leukemia/Lymphoma +

Peripheral T-Cell Lymphoma +

Refractory Anemia +

Leukemia +

Mixed Phenotype Acute Leukemia, B/Myeloid, NOS +

Acute Myeloid Leukemia With Myelodysplasia-Related Changes +

Myeloid Neoplasm +

Mixed Phenotype Acute Leukemia, T/Myeloid, NOS +

Malignant Uterine Neoplasm +

Acute Leukemia Of Ambiguous Lineage +

Indolent Non-Hodgkin Lymphoma +

Cancer +

Lung Carcinoma +

T-Cell And NK-Cell Neoplasm +

Glioblastoma +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

T-Cell Non-Hodgkin Lymphoma +

Therapy-Related Myeloid Neoplasm +

Esophageal Squamous Cell Carcinoma +

Cervical Carcinoma +

Anaplastic Astrocytoma +

Gallbladder Carcinoma +

Prostate Carcinoma +

Bile Duct Carcinoma +

Sarcoma +

Primary Myelofibrosis +

Soft Tissue Sarcoma +

Histiocytic And Dendritic Cell Neoplasm +

Gastric Adenocarcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Neuroblastoma +

Rhabdomyosarcoma +

Plasma Cell Neoplasm +

Acute Bilineal Leukemia +

Adult Acute Lymphoblastic Leukemia +

Aggressive Systemic Mastocytosis +

Angioimmunoblastic T-Cell Lymphoma +

Aplastic Anemia +

B-Cell Lymphoblastic Lymphoma +

Blastic Plasmacytoid Dendritic Cell Neoplasm +

Bronchogenic Carcinoma +

Desmoplastic Small Round Cell Tumor +

Ewing Sarcoma +

Hepatosplenic T-Cell Lymphoma +

Langerhans Cell Histiocytosis +

Mast Cell Leukemia +

Mature B-Cell Lymphoma/Leukemia +

Mediastinal Large B-Cell Lymphoma +

Myelodysplastic Syndrome With Excess Blasts-1 +

Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +

Neurofibromatosis Type 1 +

Polycythemia Vera +

Secondary Myelodysplastic Syndrome +

Small Lymphocytic Leukemia +

T-Cell Lymphoblastic Lymphoma +

Therapy-Related Chronic Myelomonocytic Leukemia +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.